A credit-card-sized heart test was compared with a standard heart tracing. Results will be presented Nov. 1.
HeartBeam (NASDAQ: BEAT) presented pilot study results comparing its 3D ECG technology to standard 12-lead ECG for detecting acute coronary syndrome. The study, ALIGN-ACS, will inform the design of HeartBeam’s planned U.S. pivotal study. HeartBeam received FDA Breakthrough Device Designation for heart attack assessment and was accepted into the FDA’s Total Product Life Cycle Advisory Program (TAP). Results will be presented at TCT 2026.
How this was made
The 30-second read
Why it matters
The disclosure supports the company’s planned US pivotal study design and highlights regulatory pathway progress (Breakthrough Device Designation and inclusion in FDA TAP), but it does not provide new clinical outcomes or an FDA decision.
Market read
This is a pre-event clinical-development update tied to an upcoming conference presentation, with potential sentiment impact but limited immediate trading signal due to lack of new quantitative results.
What to watch
Traders may discount the catalyst until the pivotal study design details and actual clinical endpoints/results are released, not just the planned comparison and FDA program status.
Background
ALIGN-ACS is a pilot study comparing HeartBeam’s credit-card-sized 3-lead 3D ECG technology against a standard 12-lead ECG for acute coronary syndrome detection, with results to be presented at TCT 2026.
Ticker impact
HeartBeam will present ALIGN-ACS pilot results comparing its HeartBeam 3D ECG system versus standard 12-lead ECG for detecting acute coronary syndrome at TCT 2026.
Likely limited near-term reaction as investors weigh investigational pilot data versus the need for a larger pivotal study.
The article discloses a planned abstract presentation and reiterates FDA Breakthrough Device Designation and TAP acceptance, but provides no new efficacy/safety results or FDA action.
Market effects
Adds incremental momentum to the portable/3-lead ECG and ACS detection narrative within medical devices and digital cardiology.
No clear regional market linkage beyond US-listed biotech sentiment.
Primarily relevant to global cardiology conference participants and investors tracking FDA-designated device pathways.
Counterpoint
Without disclosed pilot performance metrics, the news may be more promotional than decision-useful, limiting follow-through in the stock.
Key entities
- companyHeartBeam, Inc.
NASDAQ-listed medical technology company developing 3D ECG hardware and synthesis software for cardiac assessment.
- clinical_studyALIGN-ACS pilot study
Pilot comparison of HeartBeam’s HeartBeam System versus standard 12-lead ECG in emergency department patients for ACS detection.
- conferenceTCT 2026
Cardiovascular conference where the abstract presentation is scheduled for Nov. 1.
- regulatory_programFDA Breakthrough Device Designation
FDA designation referenced as supporting the heart attack assessment program.
- regulatory_programFDA Total Product Life Cycle Advisory Program (TAP)
FDA program acceptance referenced as supporting development planning.
